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Abstract
This review provides a brief overview of the state-of-the-art molecular pathology approaches emphasizing the increasingly 
important pathology role in clinical precision cancer medicine. Recent advances in molecular biology and genetics have tre-
mendously affected the practice of anatomic pathology, gradually transforming it from a morphology-based into a molecular-
based discipline. Molecular diagnostics has a long tradition in pathology, especially in clinical pathology. The improvement of 
methodology for genomic testing in recent years has made it one of the cornerstones of precision cancer medicine. The decisions 
related to cancer treatments are no longer solely based on the histopathological diagnosis. Various genomic analyses of human 
cancers are being incorporated into diagnostic and decision-making algorithms. Conclusion.  The pathologists continue to play 
an essential role in developing and implementing molecular and genomic tests in practice and communicate the results and 
their relevance with clinicians. Such activities are of utmost importance for successfully translating scientific advancements into 
a benefit to patients (“next-generation pathologists”). 
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Introduction
In the early 19th century, diagnostic pathology 
was predominantly restricted to a postmortem as-
sessment, and description of macroscopic tumor 
spread in the dissection room (1). However, pa-
thology’s principles and practice changed dramat-
ically with the establishment of light microscopy 
and histopathologic investigations in the second 
half of the 19th century by the renowned German 
pathologist Dr. Rudolf Virchow (1821–1902), who 
is considered the ‘father of modern pathology.’ 
Thanks to these advances, it became possible to 
investigate different microscopic characteristics of 
various human diseases, including cancer (1). 
Microscopic classification of tumors has, over 
the last 100 years, helped in improving the patho-
logic diagnosis of neoplastic diseases, predicting 
tumor behavior and thus formulating the prog-
nosis for each case and thus facilitating clinical 
decision-making. Traditional cancer classification 
is based on microscopic evaluations, focusing on 
various clinicopathological features of tumors, 
such as tumor morphology (type), grade, surgical 
margins, vascular/lymphatic invasion, lymph node 
assessment and routine analysis of biomarkers. Pa-
thologists traditionally utilize frozen sections that 
enable a rapid gross and microscopic tissue analy-
sis and guide surgeons’ hands during surgery (e.g., 
providing provisional diagnosis, assessing surgical 
margins, and identifying tissue of origins) (2) (Fig-
ure 1). However, none of those mentioned above 
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These features include not only cell proliferation/
replication, apoptosis, (neo)angiogenesis, down-
regulation of growth suppressors, invasion/metas-
tasis (5) but also the altered metabolic properties, 
genomic instability/mutations, escape from im-
mune surveillance, and tumor-promoting inflam-
mation (6). This evolutionary model of carcino-
genesis can efficiently explain the complexity and 
the marked heterogeneity that characterize the 
vast majority of human cancers (7). Recent find-
ings from high-throughput, multiplex/massively 
parallel technologies (assays) added important 
information about the underlying genomic altera-
tions and human cancers’ biological events. These 
findings provide insights into novel treatment mo-
dalities and allow for patient stratifications that 
impact cancer patients’ management (7).
In the previous two decades, with the increas-
ing understanding of human cancer’s molecular 
genomic drivers, the number of novel biomark-
ers and the subsequent development of targeted 
pharmaceutical treatments have dramatically in-
creased. These changes have strongly influenced 
Figure 1. A proposed algorithm for the pathology role in personalized (precision) medicine. CSF=Cerebrospinal fluid; 
IHC=Immunohistochemistry; AI=Artificial intelligence; ML=Machine learning.
may capture individual cancers’ variable clinical 
courses (heterogeneity). 
The underlying basic biology of various can-
cer and their development and progression are 
still poorly understood but undoubtedly depend 
on each tumor’s genetic background. The fact that 
cancer is a genetic disorder was suspected surpris-
ingly early (1914) in the history of cancer research 
by Dr. Theodor Boveri. He presented a systematic 
somatic mutation theory of cancer (3). Accord-
ing to Boveri’s hypothesis, chromosomal changes 
caused the transition from normal to the cells’ 
malignant proliferation (3). However, the detailed 
oncogenesis model was first described by Nowell 
some 50 years later (4). Dr. Nowell provided evi-
dence that the accumulation of mutations in can-
cers over time makes them more advanced and 
aggressive, increasing their metastatic potential. 
In 2000, Drs. Hanahan and Weinberg elegantly 
explained detailed cancer evolution in their semi-
nal papers “The hallmarks of cancer” (5, 6). The 
authors outlined the principal biological charac-
teristics of carcinogenesis (“hallmarks of cancer”). 
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diagnostic pathology practice, gradually trans-
forming it from morphology-based into molecu-
lar-based discipline. 
This brief review will discuss and critically as-
sess molecular biology’s contributions to diagnos-
tic pathology and precision cancer medicine.
Precision Medicine and Pathology
The concept of personalized medicine stems from 
the advances in biotechnology, molecular biology, 
and genetics. It affects the diagnostic tests that may 
guide the therapeutic options based on individual 
(specific) characteristics (1). Using massively par-
allel, high-throughput technologies, these advanc-
es enable detecting minute and precise changes at 
different molecular (DNA, RNA, protein) levels 
in enormous quantity and variety and at an ever-
increasing speed. The methods include DNA/
RNA sequencing, mass spectrometry, microarray 
technologies, comparative genomic hybridization, 
digital polymerase chain reaction (PCR), each of 
which generates an enormous quantity of infor-
mation called “big data” (8, 9).
In the U.S., the Personalized Medicine Coali-
tion defined personalized medicine as the “tailor-
ing of medical treatment to each patient’s charac-
teristics. It does not mean that drugs (or medical 
devices) are developed to be unique to a patient 
but rather the ability to classify individuals into 
subpopulations that differ in their susceptibility to 
a particular disease or their response to a specific 
treatment. Therefore, the preventive or therapeutic 
interventions can be concentrated on those who 
will benefit, sparing expense, and adverse effects 
for those who will not” (10).  On the other hand, 
the U.S. National Cancer Institute (NCI) defines 
personalized medicine as “a form of medicine that 
uses information about a person’s genes, proteins, 
and environment to prevent, diagnose, and treat 
disease” (11). The key features of personalized 
medicine include identifying populations (or indi-
vidual patients) who are candidates for treatment, 
either by identifying patient/disease characteristics 
that are likely to benefit or show no improvement/
develop adverse effects from treatment (12). Von 
Hoff and collaborators at TGen and Caris Life Sci-
ences were the pioneers in the precision medicine 
treatment approach, demonstrating that molecu-
lar profiling of patients’ tumors is an efficient ap-
proach to identifying potential targets and select-
ing the best treatments for their refractory cancers 
(13). Since then, numerous studies have confirmed 
the clinical relevance of molecular profiling and 
personalized medicine in cancer treatment lead-
ing to the paradigm shift in cancer treatment (9). 
Even though personalized medicine’s potential 
benefits are already evident (e.g., enhanced thera-
peutic efficacy and increased safety of targeted 
drugs), its uptake by health care systems varies 
across the globe. Generally, it remains limited at 
this time (14). However, it is anticipated that, as 
a scientific understanding of cancer progresses at 
the molecular level, personalized medicine ap-
proaches to cancer diagnosis and treatment will 
become more common. For example, the number 
of personalized medicine devices that have been 
commercialized in Europe quadrupled between 
2006 and 2011 (10). The development of therapeu-
tic products (devices) that are paired with diag-
nostic tests is also rapidly increasing. In December 
2013, the Food and Drug Administration (FDA) 
approved the first next-generation sequencer 
(NGS) (Illumina’s MiSeqDx) for commercial use 
in the United States (15). This platform’s approval 
made possible the dozens of genomic information 
in clinical practice, and markedly expanded this 
technology’s clinical utility to guide patients’ care 
(15). In 2017, the FDA approved the Foundation-
One CDx (Foundation Medicine, Inc.) as the first 
comprehensive, FDA-approved tissue-based com-
panion diagnostic (CDx) assay that is validated 
for all solid tumors (16). In August 2020, the FDA 
granted approval for the first liquid biopsy-based 
NGS CDx test, The Guardant360 CDx (The Guar-
dant Health, Inc.) (17). The Guardant360 CDx uti-
lizes liquid biopsy and NGS technology to detect 
55 different genomic alterations, including EGFR 
gene mutations in patients with NSCLC from 
circulating cell-free DNA (cfDNA). Besides, sev-
eral comprehensive NGS-platforms are currently 
available (e.g., Caris MI profile, Tempus xT assay, 
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Invitae Multi-Cancer Panel) (18) and are being 
increasingly used in cancer decision-making and 
treatment (19) (please refer to the next paragraph 
for more details). Recently, the European Society 
of Medical Oncology (ESMO) Precision Medicine 
Working up came out with their recommenda-
tions for the use of NGS testing for patients with 
metastatic cancers (20). Using the ESMO Scale for 
Clinical Actionability of molecular Targets (ES-
CAT), the ESMO group found concrete evidence. 
It strongly recommended routine NGS testing for 
patients with metastatic NSCLC, prostate, ovar-
ian cancers, and cholangiocarcinoma. Besides, 
they recommended NGS testing for several other 
common cancers such as colorectal cancer, small 
cell lung cancer (SCLC), endometrial cancer, neu-
roendocrine tumors, salivary, thyroid, and vulvar 
cancers (mainly for the tumor mutational burden 
(TMB) assessment as a predictive biomarker for 
immune checkpoint inhibitors) (20).
The Concept of Companion Diagnostic 
Tests (CDx)
The rise of precision medicine in pathology ac-
celerated in the 1980s with the diagnostic use of 
automated immunohistochemistry (IHC) (21, 22). 
Since that time, IHC has been substantially im-
proved, standardized, and its clinical utility in can-
cer diagnostics has been markedly expanded, par-
ticularly in recent years (23-27). IHC is an essen-
tial tool for cancer diagnostics and tumor typing 
(Figure 1). However, it has been increasingly used 
as a reliable and affordable method for precision 
medicine purposes. The vast majority of diagnostic 
tests are developed in the individual laboratories 
and are designated as a laboratory (or in-house) 
developed tests (LDT). However, several IHC tests 
are now designated as “companion diagnostic” or 
“complementary diagnostic” tests to indicate their 
status concerning the FDA approval/clearance sta-
tus. Although IHC is a relatively simple and widely 
utilized method, frequently fully automated in 
most pathology laboratories, its interpretation is 
entirely subjective; hence a strict training/valida-
tion processes must be applied. 
A companion diagnostic device is defined as 
“an in vitro diagnostic device (IVD) or an imag-
ing tool that provides information that is essential 
for the safe and effective use of a corresponding 
therapeutic product” (28). The use of an IVD com-
panion diagnostic test with a specific therapeutic 
product is stipulated in the instructions for use in 
the labeling of both the diagnostic device and the 
corresponding medicinal product and the label-
ing of any generic or biosimilar equivalents of the 
therapeutic product. In other words, a CDx test is 
required before a specific treatment to determine 
eligibility. On the other hand, although predictive, 
a complementary diagnostics test is not needed for 
the drug’s prescription. The concept of precision 
medicine is accompanied by various CDx tests 
that have become increasingly approved and used 
for targeted treatment purposes (29) [a full list of 
companion diagnostic devices that have been ap-
proved by the FDA is available at its website (28)].
One of the earliest CDx relied on the identifi-
cation of HER2/erbB2 gene amplification (in-situ 
hybridization) or HER2 protein overexpression 
(immunohistochemistry) in breast and later in 
gastric/gastroesophageal junction (GEJ) cancers 
for the treatment with various anti-HER2 thera-
peutics such as trastuzumab and pertuzumab 
(monoclonal antibodies) and lapatinib (a small 
molecule tyrosine kinase inhibitor that inhibits 
HER2 specifically) (30-32) (Table 1).
Additional examples of commonly used CDx 
assays include the assessment of C-KIT (CD117) 
and PDGFRα mutations in gastrointestinal stro-
mal tumors (GIST) (33), tyrosine kinase muta-
tions affecting the Epidermal growth factor recep-
tor (EGFR) gene, and EML-ALK gene rearrange-
ments in non-small cell lung cancer (NSCLC) (34-
36), and mutations in the BRAF gene in malignant 
melanoma (37). Notably, most of these genetic al-
terations have a substantial potential to render tu-
mors susceptible to specific inhibitors mentioned 
above. In addition to diagnostic PCR or in-situ hy-
bridization-based assays, IHC testing, performed 
by pathologists, is robust, genomic alteration-spe-
cific, cheap, and consequently utilized in a clinical 
setting. For instance, the ALK 5A4 IHC assay has 
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been confirmed as a reliable screening diagnostic 
test for ALK-rearranged NSCLCs and is associ-
ated with treatment response and survival (38). 
Similarly, c-Kit expression using c-Kit PharmDx 
(Agilent) is indicated in both differential diagno-
sis of gastrointestinal stromal tumors (GIST) (95% 
positive) and in selecting the GIST patients that 
are eligible for treatment with imatinib mesylate 
(Gleevec). EGFR pharmDxTM is another FDA-
approved IHC-based assay that was supposed to 
identify colorectal cancer patients who are eligible 
for anti-EGFR-treatment modalities such as cetux-
imab or panitumumab (Table 1). However, later 
studies revealed that EGFR protein expression is 
not a clinically useful predictive biomarker to ce-
tuximab response in patients with CRC (39, 40).
Specific biomarkers can also indicate when pa-
tients are less likely to respond to a specific thera-
py, e.g., KRAS or NRAS mutations make colorectal 
cancers unresponsive to anti-epidermal growth 
factor receptor (anti-EGFR) therapies such as ce-
tuximab or panitumumab (40-42). Similarly, spe-
cific EGFR gene mutations in NSCLC (e.g., point 
mutation T790M) are responsible for approxi-
mately 50% of acquired resistance to the EGFR 
tyrosine kinase inhibitors (43).
In contrast to those mentioned above single 
genomic assays, FoundationOne CDx is the first 
FDA-approved comprehensive tissue-based CDx 
Table 1. Some of the Commonly Used Single Diagnostic Tests [Diagnostic Antibodies (Immunohistochemistry) and Probes 
















22c3 (DAKO Agilent) TPS 0, 1-49, ≥50 NSCLC Pembrolizumab




Other companion diagnostic (CDx) single tests
ALK Testing 
ALK D5F3 Ventana (IHC)









Identification of ALK gene 
rearrangements with its 




anti-HER2 (4B5) (Ventana) (IHC)















DAKO c-Kit PharmDx (IHC)
Positive/
negative
Any expression in cancer cells GIST Imatinib mesylate
DAKO EGFR PharmDx (IHC)
Positive/
negative





All the listed assays have been approved by the Food and Drug Administration/FDA/ (28). ALK=Anaplastic lymphoma kinase; CEP17=Centromere of chromo-
some 17; CPS=Combined positive score is defined as the number of PD-L1 positive cells (cancer cells, lymphocytes, and macrophages) divided by the total 
number of viable tumor cells, multiplied by 100; EGFR=Epidermal growth factor receptor; FISH=Fluorescent in situ hybridization; GEJ=carcinoma Gastro-
esophageal junction carcinoma; GIST=Gastrointestinal stromal tumor; HER2=Human epidermal growth receptor 2; IC (immune cells) score=A proportion 
of the tumor area occupied by PD-L1 staining of any intensity; IHC=Immunohistochemistry; ISH=In situ hybridization; NSCLC=Non-small cell lung cancer; 
TC=Tumor cells; TNBC=Triple-negative breast cancer; TPS=Tumor proportion score. Defined as the percentage of viable cancer cells showing a partial or 
complete membrane staining at any intensity.
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that has been validated in a variety of solid tumors. 
It includes a broad panel of tested genes (N=324) 
and two genomic signatures. It has already been 
utilized in treatment decision-making for various 
solid cancers, including NSCLC, colorectal, breast, 
ovarian cancer, and malignant melanoma (44) (Ta-
ble 2). The test also provides microsatellite insta-
bility (MSI) and tumor mutational burden (TMB) 
status, both of which are essential predictive bio-
markers in immuno-oncology (I-O) treatment re-
gardless of the tumor histology (“tumor agnostic 
approach”) (please refer to the next paragraph). 
The FoundationOne CDx is also a CDx for iden-
tifying the neurotrophic receptor tyrosine kinase 
(NTRK) genes (NTRK1, NTRK2, and NTRK3) fu-
sions. All the patients whose cancers harbor any of 
these fusions and regardless of the tumor histotype 
are eligible for the treatment with an NTRK inhibi-
tor (entrectinib or larotrectinib) (Another “tumor 
agnostic approach”) (45). FoundationOne Liquid 
CDx is a similar FDA-approved CDx that explores 
potentially targetable genes using a simple blood 
sample (liquid biopsy, which is based on peripheral 
blood analysis of cell-free circulating tumor DNA). 
It is along with the Guardant360 CDx, the only 
comprehensive FDA-approved blood-based test 
that analyzes > 300 genes, making it the most com-
prehensive FDA-approved liquid biopsy CDx cur-
rently available (Table 2). Besides, FoundationOne 
Liquid CDx provides blood tumor mutational bur-
den (bTMB), MSI, and tumor fraction values. An-
other FDA-approved comprehensive molecular ge-
nomic assay is the MSK-IMPACT™ test developed 
by the Memorial Sloan Kettering Cancer Center. 
Memorial Sloan Kettering-Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IM-
PACT) covers 468 different genes, many of which 
are potentially targetable with currently available 
drugs (46). MSK-IMPACT has been shown to reli-
ably profile tumor DNA for somatic mutations in 
various solid malignancies with high accuracy and 
sensitivity (47). In contrast to the FoundationOne 
CDx, this assay is mainly used in the United States.
Immunotherapy, based on immune checkpoint 
inhibitors against programmed cell death protein 
1/programmed death-ligand 1 (PD-1/PD-L1) axis, 
has dramatically changed the cancer treatment 
paradigm and improved the outcomes of several 
common cancers such as melanoma, NSCLC, re-
nal, urothelial, cervical, gastric/gastroesophageal 
(GEJ), head and neck squamous cell and triple-
negative breast carcinomas (TNBC) (48). The ther-
apeutic breakthroughs have been followed by the 
development of predictive biomarkers of response 
to immune checkpoint inhibitors. Several of these 
biomarkers have been validated and achieved a 
companion diagnostic status, including PD-L1 
expression in tumor (T.C.) or immune cells (IC) 
tested by IHC. Tumor mutational burden (TMB) 
and microsatellite instability-high (MSI-H) status, 
determined by NGS-based assays, have also been 
approved as predictive biomarkers to immune 
checkpoint blockade (e.g., pembrolizumab) (49) 
(Table 2). Other potential predictive biomarkers 
[e.g., PD-1 status, PD-L1 (CD274 gene) amplifica-
tion], although extensively studied, have not been 
fully validated and consequently approved as CDx 
assays.
Multiple IHC assays with different scoring al-
gorithms have been approved for various immune 
checkpoint blockade therapies and associated can-
cers (Table 1). Several of these IHC assays have 
been approved as CDx, such as VENTANA SP142 
assay for selecting NSCLC, bladder, and TNBC pa-
tients for the treatment with immune checkpoint 
inhibitor atezolizumab. DAKO 22C3 pharmDx 
assay has been approved for testing eligibility of 
NSCLC, TNBC, gastric/GEJ, cervical, urothe-
lial, head and neck squamous cell (HNSCC), and 
esophageal squamous cell carcinoma patients for 
the treatment with pembrolizumab while DAKO 
28-8 pharmDx clone is utilized for the selection of 
NSCLC patients for the combined treatment with 
two immune checkpoint inhibitors: nivolumab 
(against PD-1) + ipilimumab (targeting cytotoxic 
T-lymphocyte-associated protein 4/CTLA-4/) 
(28). Notably, each of these assays has different 
scoring algorithms, e.g., tumor proportion score 
(TPS), combined positive score (CPS), and im-
mune cells (I.C.) score, all of which have different 
thresholds for positivity. These issues make the 
current PD-L1 IHC testing landscape very compli-
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cated. They require pathologists to be specifically 
trained for each of the proposed assays and their 
respective scoring systems.
Besides, PD-L1 status in cancer is substantially 
challenged by its complex regulation within the tu-
mor parenchyma and microenvironment (immune 
cells), its dynamic clonal and proteomic changes to 
therapy, heterogeneous host immune defects, and 
markedly variable standardization among sample 
preparation and reporting (48). Despite all the ad-
vances mentioned above, there is still an unmet 
need to optimize predictive I-O biomarkers given 
their limited clinical utility (a low response rate/
resistance in most cancers) and highly demanding 
testing and interpretation algorithms (20).
Challenges Ahead: “Next-Generation 
Pathologists” and Precision Medicine
Molecular pathology has become one of the corner-
stones of precision cancer medicine. This change 
has required enormous efforts from pathologists 
to gain and demonstrate expertise and skills in this 
rapidly evolving era (50). Simultaneously, the par-
adigm shift allowed for the discipline of pathology 
to reinvent itself as a leading diagnostic discipline 
in the precision medicine era. Indeed, this would 
imply additional and continuous efforts to educate 
pathologists in using genomic and molecular data 
and interpret novel diagnostic tests and proce-
dures. Therefore, the dissemination of knowledge 
on molecular pathology among pathologists by in-
corporating the courses in postgraduate training 
programs for trained pathologists and improving 
pathology residency training programs are critical 
for the future of diagnostic molecular pathology 
(51). In this regard, several countries have already 
taken the necessary measures. Thus, the Dutch So-
ciety of Pathology has launched a 2-year training 
program in molecular pathology, while the Royal 
College of Pathologists has a fellowship in molecu-
lar pathology for clinical scientists. In the United 
States, the Association of Molecular Pathology has 
also developed a molecular pathology curriculum 
for medical laboratory scientists (52). At the same 
time, the American Board of Pathology offers cer-
tification for the pathologist completing at least 12 
months of training in an ACGME (The Accredi-
tation Council for Graduate Medical Education) 
accredited molecular genetic pathology program 
(53). 
Another essential aspect in which the patholo-
gists play a crucial role is developing and imple-
menting molecular tests in clinical practice and 
communicating the obtained results with other 
diagnostic disciplines (e.g., microbiology, clinical 
chemistry, genetics, and immunology) (15, 54-56) 
and clinicians (Figure 1). Pathologists also play 
a crucial role in optimizing the samples for mo-
lecular profiling. They are also responsible for the 
proper and selective use of the available specimens 
Table 2. Overview of the Commonly Used and FDA-Approved Comprehensive Companion Diagnostic Tests
Assay* Technology Gene panel† Indications‡ Drugs
FoundationOne 
CDx§




Multiple cancers (NSCLC, colon, 
breast, ovary, melanoma)






















TAGRISSO (Osimertinib) and 
other targeted drugs
*Manufacturer; †Predictive biomarkers; ‡Cancer subtypes; §Tissue-based assay; ||Based on peripheral blood analysis of cell-free circulating tumor DNA (cfDNA) 
(=liquid biopsy); EGFR=Epidermal Growth Factor Receptor; FDA=Food and Drug Administration; MSI=Microsatellite instability; NGS=Next-generation se-
quencing; NSCLC=Non-small cell lung cancer; TMB=Tumor mutational burden.
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to enhance predictive tests’ clinical utility. New, 
complementary diagnostic methods have also 
been launched, e.g., the sequence analysis of cell-
free tumor DNA isolated from plasma or urine 
(=liquid biopsy) (Figure 1). Liquid biopsy and the 
traditional tissue samples (biopsy, cytology) are of 
utmost importance for identifying biomarkers for 
personalized medicine. Increased availability of 
diagnostic tests and a growing emphasis on per-
sonalized medicine have been approached by the 
novel, revolutionary technologies such as machine 
learning (ML) and artificial intelligence (A.I.), 
both of which could greatly help in analyzing the 
“big data” and identifying the proper biomarkers 
for precision medicine (treatment) and diagnos-
tics (“personalized diagnosis”) (57, 58) (Figure 
1). Both methods are rapidly evolving and are 
believed to contribute to precision medicine and 
other healthcare fields. 
All of the activities mentioned above contrib-
ute to a successful translation of the scientific ad-
vancements into a benefit to patients (“next-gener-
ation pathologists”). In this regard, the European 
Society of Pathology (ESP) and the Royal Col-
lege of Pathology (RCPath) groups proposed the 
guidelines for laboratories performing molecular 
pathology for cancer patients (52). The guideline 
encompasses all the essential issues related to mo-
lecular pathology testing, including preanalytical 
considerations, sample receipt and handling (fixa-
tion and processing), DNA and RNA extraction, 
selection of appropriate analytical method(s), and 
quality control (both internal and external) (52). 
College of American Pathologists (CAP) has also 
been actively developing numerous evidence-
based guidelines about preanalytical and analyti-
cal aspects of diagnostic and molecular pathology. 
These guidelines also include precision medicine 
biomarkers and CDx assays such as estrogen re-
ceptor (ER), progesterone receptor (PR) and 
HER2 (breast cancer), various predictive biomark-
ers in NSCLC and CRC, biomarkers for prostate 
cancer, Human Papillomavirus (HPV) testing in 
HNSCC, etc. (59). Similar initiatives have been 
taken by international external quality assurance 
(EQA)  agencies [e.g., UK NEQAS ICC & ISH, 
NordiQC, and European Molecular Quality Net-
work (EMQN)], who put joint efforts to publish 
the guidelines for EQA. These guidelines aim to 
improve molecular tests’ performance for preci-
sion medicine purposes (60).   
Conclusions and Future Directions
The practice of diagnostic pathology has been sub-
stantially changed in the previous years due to the 
advances in molecular diagnostics and targeted 
treatment (precision medicine). Molecular pathol-
ogy has become one of the cornerstones of preci-
sion cancer medicine. Although “the next-gener-
ation pathologists” have already been launched, 
further and continuous educational efforts must 
fully implement the paradigm shift into diagnos-
tic molecular pathology practice and reinvent it 
as a leading diagnostic discipline in the precision 
medicine era. Most of the approved and validated 
predictive biomarkers in precision medicine still 
require further optimization and standardization. 
There is an unmet need for novel and more reliable 
predictive tests (biomarkers) given a low response 
rate and common resistance for most approved 
targeted treatment modalities.  
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